Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Sponsor
Hoffmann-La Roche
Study ID
NCT02461290
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.

Key Dates

Start date
Apr 30, 2008
Status verified
Aug 2015
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013

Study Design

Enrollment
99 participants (actual)

Arms

  • Arm: Combination Therapy
    Rituximab 375mg/m2, on day 1 of each cycle of chemotherapy, total of 8 infusions. Chemotherapy according to standard regimens.

Primary Outcome Measure

Number of Participants With an Adverse Event (AE), Serious AE, or Death Related to AE [ Time Frame: Up to 3 years (at Screening, Baseline, end of induction therapy, and in accordance with routine practice) ]

Related Studies